CCG
BEAT

Chatham Capital Group’s BioTelemetry, Inc. BEAT Stock Holding History

Chatham Capital Group’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,794
Closed -$2.22M – 179
2020
Q4 		$2.22M Sell
30,794
-575
-2% -$30.1K 0.5% 60
2020
Q3 		$1.43M Sell
31,369
-98
-0.3% -$4.1K 0.35% 66
2020
Q2 		$1.42M Buy
31,467
+159
+0.5% +$7.12K 0.37% 67
2020
Q1 		$1.21M Sell
31,308
-33
-0.1% -$1.52K 0.36% 70
2019
Q4 		$1.45M Sell
31,341
-890
-3% -$38.5K 0.36% 77
2019
Q3 		$1.31M Buy
32,231
+110
+0.3% +$4.75K 0.34% 80
2019
Q2 		$1.55M Sell
32,121
-276
-0.9% -$14.5K 0.39% 71
2019
Q1 		$2.03M Buy
32,397
+214
+0.7% +$14.7K 0.52% 53
2018
Q4 		$1.92M Buy
32,183
+3,198
+11% +$192K 0.53% 47
2018
Q3 		$1.87M Sell
28,985
-500
-2% -$27.9K 0.47% 49
2018
Q2 		$1.33M Buy
29,485
+625
+2% +$24.9K 0.35% 68
2018
Q1 		$896K Sell
28,860
-1,300
-4% -$42.8K 0.24% 85
2017
Q4 		$902K Buy
30,160
+710
+2% +$20.6K 0.25% 80
2017
Q3 		$972K Hold
29,450
– – 0.28% 77
2017
Q2 		$985K Buy
+29,450
New +$879K 0.27% 78

Other funds holding BEAT

LCM
Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Chatham Capital Group's BEAT Position: Q1 2021 in Review

Chatham Capital Group sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 30,794 shares — an estimated $2.22M sold.

Chatham Capital Group first reported a position in BEAT in Q2 2017 and held it in 15 quarters. The position peaked at $2.22M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • Chatham Capital Group reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • Chatham Capital Group sold 30,794 BioTelemetry, Inc. shares in Q1 2021, an estimated $2.22M.
  • Chatham Capital Group first reported a position in BioTelemetry, Inc. in Q2 2017 and held it in 15 quarters.
  • Chatham Capital Group's BioTelemetry, Inc. position peaked at $2.22M in Q4 2020.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Chatham Capital Group's 13F filing for Q1 2021, filed 29 Apr 2021.